logo
Plus   Neg
Share
Email

Astellas Pharma, FibroGen Announce Approval Of Evrenzo In Japan - Quick Facts

Astellas Pharma Inc. (ALPMY,ALPMY) and FibroGen, Inc. (FGEN) reported the approval of Evrenzo (generic name: roxadustat) in Japan for the treatment of anemia associated with chronic kidney disease in dialysis patients. This is the first approval for roxadustat through the Astellas and FibroGen association.

Roxadustat is also in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes.

Peony Yu, Chief Medical Officer, FibroGen, said: "With this approval in Japan, NDA approval in China, and EU MAA and US NDA preparations underway, we are another step closer to our goal of addressing the significant unmet medical need of patients living with anemia of chronic kidney disease, worldwide."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Fast food chain Krystal Company has filed for bankruptcy, according to reports. The Atlanta-based Krystal filed for Chapter 11 on Sunday in the U.S. Bankruptcy Court in Atlanta. In the filing, the company reportedly disclosed assets between $10 million and $50 million, and liabilities between $50 million and $100 million. The chief executive officer of Google's parent company Alphabet called for artificial intelligence or AI to be regulated, noting that there are real concerns about the potential negative consequences of the technology. According to Alphabet CEO Sundar Pichai, there are real concerns about the negative consequences of AI, from deepfakes to nefarious uses of facial recognition. Walt Disney Co.'s (DIS) streaming service Disney+ will be launched on March 24 in the UK and other markets in the Western Europe, one week earlier than originally planned on March 31. Pricing also been confirmed at 5.99 pounds/6.99 euros per month or 59.99 pounds/69.99 euros for an annual subscription....
Follow RTT
>